Episode
Live From WCLC 2026: Sunday Highlights
- Podcast
- Lung Cancer Considered
- Published
- Sep 14, 2026
- Duration seconds
- 2827
- Processing state
not_requested- Audio
- https://feeds.soundcloud.com/stream/2399983554-lungcancerconsidered-live-from-wclc-2026-sunday.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/lung-cancer-considered-246259/episodes/live-from-wclc-2026-sunday-highlights/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/lung-cancer-considered-246259/live-from-wclc-2026-sunday-highlights.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
From the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, Dr. Narjust Florez talks with Dr. Chad Rusthoven about MAVERICK, the trial that tested MRI surveillance alone against prophylactic cranial irradiation in small cell lung cancer, and with Dr. Chul Kim about the final overall survival results of PAPILLON, amivantamab plus chemotherapy in EGFR exon 20 insertion NSCLC. Both guests share what patients and community oncologists should take from the data. Guests: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Chad G. Rusthoven, MD Adjunct Associate Professor University of Colorado University of North Carolina at Chapel Hill